These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35836506)

  • 1. Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis.
    Xiao X; Zhang G; Sun B; Wang C; Wang X; Kong F; Jia Y
    Transl Cancer Res; 2022 Jun; 11(6):1472-1482. PubMed ID: 35836506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
    Shi Y; Lei K; Jia Y; Ni B; He Z; Bi M; Wang X; Shi J; Zhou M; Sun Q; Wang G; Chen D; Shu Y; Liu L; Guo Z; Liu Y; Yang J; Wang K; Xiao K; Wu L; Yi T; Sun D; Kang M; Ma T; Mao Y; Shi J; Tang T; Wang Y; Xing P; Lv D; Liao W; Luo Z; Wang B; Wu X; Zhu X; Han S; Guo Q; Liu R; Lu Z; Zhang J; Fang J; Hu C; Ji Y; Liu G; Lu H; Wu D; Zhang J; Zhu S; Liu Z; Qiu W; Ye F; Yu Y; Zhao Y; Zheng Q; Chen J; Pan Z; Zhang Y; Lian W; Jiang B; Qiu B; Zhang G; Zhang H; Chen Y; Chen Y; Duan H; Li M; Liu S; Ma L; Pan H; Yuan X; Yuan X; Zheng Y; Gao E; Zhao L; Wang S; Wu C
    Cancer Commun (Lond); 2021 Sep; 41(9):889-903. PubMed ID: 34184418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab biosimilar candidate TAB008 compared to Avastin
    Lu S; Qin S; Zhou Z; Chen J; Gu K; Sun P; Pan Y; Yu G; Ma K; Shi J; Sun Y; Yang L; Chen P; Liu A; He J
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5907-5914. PubMed ID: 36595042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis.
    Yang L; Liu M; Cao X; Li N; Zheng B; Deng J; Cai H
    Ther Adv Med Oncol; 2022; 14():17588359221130501. PubMed ID: 36312816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
    Trukhin D; Poddubskaya E; Andric Z; Makharadze T; Bellala RS; Charoentum C; Yañez Ruiz EP; Fulop A; Hyder Ali IA; Syrigos K; Katgi N; Lopez Chuken YA; Rumyana I; Reyes-Igama J; Costamilan RC; Del Campo García A; Florez A; Paravisini A; Millan S;
    BioDrugs; 2021 Jul; 35(4):429-444. PubMed ID: 33914256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
    Syrigos K; Abert I; Andric Z; Bondarenko IN; Dvorkin M; Galic K; Galiulin R; Kuchava V; Sriuranpong V; Trukhin D; Zhavrid E; Fu D; Kassalow LM; Jones S; Bashir Z;
    BioDrugs; 2021 Jul; 35(4):417-428. PubMed ID: 34264503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer.
    Yang Y; Wu B; Huang L; Shi M; Liu Y; Zhao Y; Wang L; Lu S; Chen G; Li B; Xie C; Fang J; Yang N; Zhang Y; Cui J; Song Y; Zhang C; Mei X; Cao B; Yang L; Cheng Y; Ying K; Sun T; Ren B; Yu Q; Liao Z; Pei Z; Wang M; Zhou J; Yu S; Feng G; Wan H; Wang H; Gao S; Wang J; An G; Geng Y; Ji Y; Yuan Y; Ma S; Jia Z; Hu M; Zhou H; Yu J; Sun X; Zhang L
    Transl Lung Cancer Res; 2019 Dec; 8(6):989-999. PubMed ID: 32010577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
    Liu Y; Li HM; Wang R
    Front Med (Lausanne); 2021; 8():616380. PubMed ID: 34277647
    [No Abstract]   [Full Text] [Related]  

  • 10. The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Zhou Y; He M; Li R; Peng Y; Li F; Li S; Yang M
    Biomed Res Int; 2021; 2021():5537899. PubMed ID: 34532503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
    Socinski MA; Waller CF; Idris T; Bondarenko I; Luft A; Beckmann K; Vishweswaramurthy A; Loganathan S; Donnelly C; Hummel MA; Shapiro R; Woods M; Rao A; Nayak VG; Ranganna G; Barve A
    Ther Adv Med Oncol; 2021; 13():17588359211045845. PubMed ID: 34819997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
    Stroyakovskiy DL; Fadeeva NV; Matrosova MP; Shelepen KG; Adamchuk GA; Roy B; Nagarkar R; Kalloli M; Zhuravleva D; Voevodin GD; Shustova MS; Kryukov F
    BMC Cancer; 2022 Feb; 22(1):129. PubMed ID: 35105329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.
    Sakharkar P; Kurup S
    Diseases; 2023 Oct; 11(4):. PubMed ID: 37873790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis.
    Zhou K; Zhao S; Guo W; Ding L
    Medicine (Baltimore); 2020 Jan; 99(3):e18771. PubMed ID: 32011468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
    Yang K; Wang YJ; Chen XR; Chen HN
    Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials.
    Han G; Li C; Yi P
    Front Pharmacol; 2024; 15():1293039. PubMed ID: 38318133
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis.
    Hu Y; Chen P; Xiang F
    J Oncol; 2023; 2023():8740221. PubMed ID: 36816360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis.
    Zhou G; Guo L; Xu J; Tang K; Chen J
    Ther Adv Med Oncol; 2024; 16():17588359241227677. PubMed ID: 38304850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.